Jazz Pharmaceuticals (JAZZ) Non Operating Income (2011 - 2026)

Jazz Pharmaceuticals' Non Operating Income history runs 16 years deep, the most recent figure standing at -$39.9 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 25.7% year-over-year to -$39.9 million in Q1 2026; TTM through Mar 2026 was -$181.2 million, a 19.69% increase from a year earlier, with the FY2025 full-year figure at -$195.1 million, up 18.08% from the prior year.
• Non Operating Income climbed to -$39.9 million in Q1 2026 per JAZZ's latest filing, from -$45.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$39.9 million in Q1 2026 and bottomed at -$80.2 million in Q3 2022.
• The 5-year median for Non Operating Income is -$63.2 million (2022), against an average of -$61.8 million.
• Across the five-year window, Non Operating Income sank 158.2% in 2022 and gained 27.11% in 2024, its largest moves.
• Year by year, Non Operating Income stood at -$74.1 million in 2022, then increased by 5.13% to -$70.3 million in 2023, then climbed by 27.11% to -$51.3 million in 2024, then grew by 11.41% to -$45.4 million in 2025, then gained by 12.13% to -$39.9 million in 2026.
• Per Business Quant, the three latest JAZZ Non Operating Income figures stand at -$39.9 million (Q1 2026), -$45.4 million (Q4 2025), and -$48.6 million (Q3 2025).